Dara says abstract accepted for conference presentation DARA BioSciences announced that the company's abstract entitled Compliance and Preference for Tamoxifen Registry, or CAPTURE, patient survey reveals potential strategies to improve long-term adherence to TAM based on choice: results of a large internet-based survey" has been accepted for poster presentation at the upcoming National Comprehensive Cancer Network 19th Annual Conference: Advancing the Standard of Cancer Care. The abstract has been selected for poster presentation during General Poster Session One on March 13. David J. Drutz M.D., DARA's CEO and Chief Medical Officer said, "We are very pleased to have our CAPTURE abstract accepted by this prominent, oncology-focused organization. Our goal for initiating CAPTURE was to generate important, patient-centric information regarding demographics and medication compliance of breast cancer patients taking tamoxifen tablets, including their expressed potential preference for a liquid formulation. We look forward to reporting the data from this study and believe the key findings will raise awareness of opportunities to help improve long-term compliance with this life-saving therapy."